MMG is accusing EU antitrust regulators of ignoring evidence that backs its Anglo American deal. Publicly fighting the review is what buyers do when remedies aren't landing — that's timeline risk, and

MMG accuses EU antitrust regulators of ignoring evidence backing Anglo American deal.